联合游离DNA与RNA分析雄激素受体:新型多分析物液体活检在转移性前列腺癌中的临床价值
该前瞻性研究纳入67例开始AR通路抑制剂或紫杉烷化疗的mCRPC患者,用新一代测序同步检测cfDNA与cfRNA中的AR异常。AR增益和AR异常累积数与更差的无进展生存和总生存独立相关,AR增益合并AR剪接变异表达与更短PSA-PFS相关,并在40例独立队列中验证。
要点
- 单管10ml血可同步完成cfDNA与cfRNA的AR谱分析,cfDNA测序成功率100%、cfRNA为88%。
- 54%的mCRPC患者存在至少一种AR异常,AR增益及异常累积数与PFS和OS独立相关。
- AR增益合并AR剪接变异表达者,在ARPI和化疗中PSA-PFS均更短,独立队列验证OS更短。
核心结论
- 新型多分析物液体活检可同时检测cfDNA和cfRNA中的AR改变,同步分析有助于理解mCRPC疾病生物学和耐药机制。
- AR增益和AR异常累积数与mCRPC患者更差的PFS和OS独立相关,AR增益合并AR剪接变异表达与更短PSA-PFS相关。
研究设计与样本
- 前瞻性纳入67例开始AR通路抑制剂(n=41)或紫杉烷化疗(n=26)的mCRPC患者。
- 使用基于新一代测序的 assay,从单管10ml血同步进行cfDNA和cfRNA谱分析。
- 采用Kaplan-Meier生存估计和多变量Cox回归分析AR异常与临床结局的关联。
- 关键发现在40例mCRPC独立队列中验证。
主要发现
- cfDNA和cfRNA分别成功测序67例(100%)和59例(88%)患者。
- AR增益与临床/影像学PFS相关(HR 3.2,p=0.01),与OS相关(HR 2.8,p=0.04)。
- AR异常累积数0 vs ≥2与PFS相关(HR 3.0,p=0.04),与OS相关(HR 2.9,p=0.03)。
- AR增益/AR-V+与ARPI的PSA-PFS相关(HR 6.7,p=0.009),与化疗的PSA-PFS相关(HR 3.9,p=0.04)。
关键数值与推荐
- AR增益与更差PFS:HR 3.2,p=0.01;与更差OS:HR 2.8,p=0.04。
- AR异常累积数0 vs ≥2与PFS:HR 3.0,p=0.04;与OS:HR 2.9,p=0.03。
- AR增益/AR-V+与ARPI的PSA-PFS:HR 6.7,p=0.009;与化疗的PSA-PFS:HR 3.9,p=0.04。
- 独立验证队列中AR增益/AR-V+与更短OS相关(HR 3.3,p=0.02)。
临床怎么用
- 对开始ARPI或紫杉烷化疗的mCRPC患者,可考虑用单管血同步检测cfDNA和cfRNA的AR异常。
- 检出AR增益、AR剪接变异或AR异常累积数高者提示预后更差,可辅助治疗决策与随访强度。
- AR增益合并AR剪接变异表达提示对ARPI和化疗的PSA应答均较短,需更密切监测。
局限性
- 样本量有限。
- 随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The androgen receptor (AR) remains a critical driver in metastatic castration-resistant prostate cancer (mCRPC). Profiling AR aberrations in both circulating DNA and RNA may identify key predictive and/or prognostic biomarkers in the context of contemporary systemic therapy. OBJECTIVE: To profile AR aberrations in circulating nucleic acids and correlate with clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: We prospectively enrolled 67 mCRPC patients commencing AR pathway inhibitors (ARPIs; n = 41) or taxane chemotherapy (n = 26). Using a first-in-class next-generation sequencing-based assay, we performed integrated cell-free DNA (cfDNA) and cell-free RNA (cfRNA) profiling from a single 10 ml blood tube. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier survival estimates and multivariable Cox regression analyses were used to assess associations between clinical outcomes and the following AR aberrations: copy number variation, splice variants (AR-V7 and AR-V9) and somatic mutations. RESULTS AND LIMITATIONS: Cell-free DNA and cfRNA were successfully sequenced in 67 (100%) and 59 (88%) patients, respectively. Thirty-six (54%) patients had one or more AR aberrations. AR gain and cumulative number of AR aberrations were independently associated with clinical/radiographic progression-free survival (PFS; hazard ratio [HR] 3.2, p = 0.01 and HR 3.0 for 0 vs ≥2, p = 0.04) and overall survival (HR 2.8, p = 0.04 and HR 2.9 for 0 vs ≥2, p = 0.03). Notably, concurrent AR gain and AR splice variant expression (AR gain/AR-V+) was associated with shorter prostate-specific antigen PFS on both ARPIs (HR 6.7, p = 0.009) and chemotherapy (HR 3.9, p = 0.04). Importantly, key findings were validated in an independent cohort of mCRPC patients (n = 40), including shorter OS in AR gain/AR-V+ disease (HR 3.3, p = 0.02). Limitations include sample size and follow-up period. CONCLUSIONS: We demonstrate the utility of a novel, multianalyte liquid biopsy assay capable of simultaneously detecting AR alterations in cfDNA and cfRNA. Concurrent profiling of cfDNA and cfRNA may provide vital insights into disease biology and resistance mechanisms in mCRPC. PATIENT SUMMARY: In this study of men with advanced prostate cancer, DNA and RNA abnormalities in the androgen receptor detected in blood were associated with poor outcomes on available drug treatments. This information could be used to better guide treatment of advanced prostate cancer.
引用
- Fettke H, Kwan EM, Docanto MM, et al. Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer. Eur Urol. 2020. PMID: 32487321. doi:10.1016/j.eururo.2020.03.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。